Peptides Similar to Retatrutide

Investigational Status Notice#

Retatrutide (LY3437943) is an investigational compound that has not been approved by the FDA or any other regulatory agency. All comparisons presented here are based on published clinical trial data and preclinical findings. Comparative efficacy and safety conclusions are limited by the absence of head-to-head trials and the early-stage nature of retatrutide's clinical development program.

Peptides Related to Retatrutide#

Retatrutide belongs to a rapidly evolving class of incretin-based peptide therapeutics targeting metabolic diseases including obesity and type 2 diabetes. The field has progressed from single-receptor GLP-1 agonists to dual GIP/GLP-1 agonists, and now to the triple GIP/GLP-1/glucagon agonist class that retatrutide represents. Understanding these related molecules provides important context for evaluating retatrutide's potential therapeutic niche and differentiating features.

The Evolution of Incretin-Based Therapies#

The development trajectory of incretin-based peptide therapies for obesity and type 2 diabetes has followed a clear pattern of increasing receptor engagement:

First generation -- Single-target GLP-1 receptor agonists: Exenatide (Byetta, 2005), liraglutide (Victoza/Saxenda, 2010/2014), and semaglutide (Ozempic/Wegovy, 2017/2021) established the GLP-1 receptor agonist class. These molecules demonstrated that targeting the GLP-1 receptor alone could produce clinically meaningful weight loss (typically 5-16% of body weight) and glycemic improvement. Semaglutide, the most potent member of this generation, achieved up to approximately 16.9% weight loss at 68 weeks in the STEP 1 trial (2.4 mg weekly dose).

Second generation -- Dual GIP/GLP-1 receptor agonists: Tirzepatide (Mounjaro/Zepbound) represented a paradigm shift by simultaneously engaging both the GIP and GLP-1 receptors. The SURMOUNT-1 trial demonstrated up to approximately 22.5% weight loss at 72 weeks with the 15 mg dose, substantially exceeding the results achievable with single-receptor GLP-1 agonists. Tirzepatide received FDA approval for type 2 diabetes in 2022 and for obesity in 2023.

Third generation -- Triple GIP/GLP-1/glucagon receptor agonists: Retatrutide is the lead investigational compound in this class, adding glucagon receptor agonism to the dual GIP/GLP-1 mechanism. Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023) showed up to 24.2% weight loss at 48 weeks with the 12 mg dose, suggesting further incremental benefit from the addition of the glucagon receptor component. However, these results are from Phase 2 trials with limited participants, and confirmation in larger Phase 3 trials is required.

Tirzepatide (Mounjaro/Zepbound)#

Mechanism Comparison#

Tirzepatide is the most closely related approved therapy to retatrutide. Both molecules share a GIP receptor agonist backbone, both incorporate Aib at position 2 for DPP-4 resistance, and both use fatty acid conjugation for albumin binding and extended half-life. The critical structural and pharmacological difference is that retatrutide adds potent glucagon receptor agonism, whereas tirzepatide has negligible glucagon receptor activity.

The glucagon receptor component in retatrutide is expected to provide several distinct metabolic effects not available through tirzepatide:

• Increased energy expenditure: Glucagon receptor activation stimulates thermogenesis and energy expenditure, potentially contributing additional caloric deficit beyond the appetite suppression mediated by GLP-1 and GIP. This provides a "push-pull" mechanism: reduced energy intake (GLP-1/GIP-driven appetite suppression) combined with increased energy output (glucagon-driven thermogenesis).

• Enhanced hepatic fat oxidation: Glucagon directly stimulates hepatic lipid oxidation and fatty acid beta-oxidation, which may be particularly relevant for patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/NASH). Phase 2 data for retatrutide showed substantial reductions in liver fat content.

• Lean mass preservation: There is a theoretical basis for glucagon receptor activation to modulate the ratio of fat mass to lean mass loss during weight reduction, although this remains to be confirmed in clinical studies.

Efficacy Comparison (Indirect)#

Direct head-to-head comparison data between retatrutide and tirzepatide do not exist. Indirect cross-trial comparisons (which must be interpreted with caution due to differences in trial design, patient populations, and endpoints) suggest:

It is important to emphasize that retatrutide's weight loss figures come from a smaller Phase 2 trial with a shorter treatment duration. Phase 3 data may differ, and until large-scale, adequately powered trials are completed, definitive efficacy comparisons cannot be made.

Safety Comparison#

Both molecules share the GI side effect profile characteristic of incretin-based therapies (nausea, vomiting, diarrhea, constipation), which are generally dose-dependent and attenuated by gradual dose escalation. Tirzepatide has the advantage of an established safety database from completed Phase 3 trials and post-marketing surveillance. Retatrutide's safety profile is based only on Phase 1-2 data, and the additional glucagon receptor component introduces theoretical risks (such as glucagon-mediated hyperglycemia) that require evaluation in larger and longer studies.

Semaglutide (Ozempic/Wegovy/Rybelsus)#

Mechanism Comparison#

Semaglutide is a selective GLP-1 receptor agonist that shares only one of retatrutide's three receptor targets. It is based on a modified GLP-1 backbone (rather than the GIP backbone used by retatrutide and tirzepatide) and uses a C18 fatty diacid conjugated at Lys26 for albumin binding. Semaglutide's mechanism of action relies entirely on GLP-1 receptor activation for appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion.

Key differences from retatrutide include:

• Single vs. triple receptor engagement: Semaglutide engages only the GLP-1 receptor, while retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors. This broader receptor engagement is hypothesized to produce greater metabolic effects.

• Absence of GIP and glucagon effects: Semaglutide does not stimulate GIP-mediated insulin secretion or glucagon-mediated energy expenditure and hepatic fat oxidation.

• Available in oral formulation: Semaglutide is uniquely available in both injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations. Retatrutide, like tirzepatide, is currently only under investigation as a subcutaneous injection.

Efficacy Comparison (Indirect)#

Semaglutide has demonstrated robust efficacy in the extensive STEP and SUSTAIN trial programs. The STEP 1 trial showed approximately 16.9% weight loss at 68 weeks with semaglutide 2.4 mg weekly in participants with obesity. While this represents substantial weight loss, it is numerically lower than the results reported for both tirzepatide and retatrutide, consistent with the hypothesis that multi-receptor engagement produces incrementally greater metabolic effects.

The SELECT cardiovascular outcomes trial demonstrated that semaglutide reduced major adverse cardiovascular events (MACE) by 20% in people with obesity and established cardiovascular disease. No cardiovascular outcomes data exist for retatrutide, and such data would be important for establishing the long-term benefit-risk profile of the investigational compound.

Survodutide (BI 456906)#

Mechanism Comparison#

Survodutide, developed by Boehringer Ingelheim and Zealand Pharma, is a dual GLP-1/glucagon receptor agonist that shares retatrutide's glucagon receptor component but lacks GIP receptor agonism. This makes survodutide the most conceptually similar investigational compound to retatrutide, with the key distinction being the absence of the GIP receptor engagement.

Survodutide's mechanism includes:

• GLP-1 receptor agonism: Appetite suppression, delayed gastric emptying, enhanced insulin secretion.
• Glucagon receptor agonism: Increased energy expenditure, hepatic fat oxidation.
• No GIP receptor activity: Lacks the additional insulinotropic and potential lipid-modulating effects of GIP receptor activation.

Clinical Development Status#

Survodutide is also in Phase 3 clinical development. Phase 2 data demonstrated approximately 18-19% weight loss at 46 weeks and significant reductions in liver fat, supporting the contribution of the glucagon receptor component to hepatic fat clearance. Survodutide is also being studied specifically for MASLD/NASH, where the glucagon-mediated hepatic lipid oxidation may be particularly beneficial.

The comparison between retatrutide and survodutide is scientifically instructive because it allows indirect assessment of the incremental contribution of GIP receptor agonism: both compounds share GLP-1 and glucagon receptor activity, but retatrutide adds GIP. The numerically greater weight loss with retatrutide (~24.2% at 48 weeks vs. ~18-19% at 46 weeks for survodutide) suggests a potential contribution from the GIP component, though cross-trial comparisons have significant limitations.

Other Related Investigational Compounds#

Pemvidutide (ALT-801)#

Pemvidutide is a dual GLP-1/glucagon receptor agonist developed by Altimmune, conceptually similar to survodutide. Phase 2 data showed approximately 15.6% weight loss at 48 weeks. Like survodutide, it lacks GIP receptor activity and thus has two of retatrutide's three targets.

Mazdutide (IBI362/LY3305677)#

Mazdutide, developed by Innovent Biologics and Eli Lilly, is a GLP-1/glucagon dual receptor agonist that has shown promising Phase 2/3 results primarily in Chinese patient populations. It shares the GLP-1 and glucagon components with retatrutide but lacks GIP agonism.

CagriSema (Cagrilintide + Semaglutide)#

CagriSema is a fixed-dose combination of cagrilintide (an amylin analog) and semaglutide (GLP-1 agonist), developed by Novo Nordisk. While this combination achieves multi-mechanism obesity treatment, it does so through a different pharmacological approach (amylin + GLP-1) rather than the triple incretin receptor strategy used by retatrutide. The REDEFINE program showed approximately 22.7% weight loss at 68 weeks.

Comprehensive Comparison Table#

Evidence Gaps and Limitations#

Several important limitations apply to all comparisons presented above:

• No head-to-head trials: No direct comparative studies between retatrutide and any approved or investigational therapy have been published. All cross-trial comparisons are indirect and subject to confounding from differences in patient populations, trial design, baseline characteristics, and endpoints.

• Phase 2 vs. Phase 3 data: Retatrutide's efficacy data come from Phase 2 trials, which typically involve fewer participants and may overestimate or underestimate effects observed in larger Phase 3 programs. Several of the comparison compounds have Phase 3 data, providing a more robust evidence base.

• Treatment duration differences: The trials cited above used different treatment durations (48 to 72 weeks), making direct numerical comparisons of weight loss percentages imprecise.

• Long-term safety unknown: The safety profile of retatrutide beyond 48 weeks is unknown. The addition of glucagon receptor agonism introduces unique theoretical risks (hyperglycemia, lean mass effects) that have not been characterized in long-term studies.

• No cardiovascular outcomes data: Unlike semaglutide (SELECT trial), retatrutide has no cardiovascular outcomes data. Such data are increasingly considered essential for establishing the overall benefit-risk profile of obesity therapies.

• Population generalizability: Phase 2 trials generally enroll narrower patient populations than Phase 3 studies. The applicability of retatrutide's efficacy and safety results to broader clinical populations remains to be established.

Given these significant evidence gaps, conclusions about the relative positioning of retatrutide within the incretin-based therapy landscape must remain provisional until Phase 3 data are available. Retatrutide's investigational status precludes clinical use outside of ongoing trials.

Related Reading#

• Retatrutide overview and research guide
• Retatrutide research evidence
• Retatrutide dosing protocols